Generic Exclusivity Usefulness Needs Review, FDA's Dickinson Says
This article was originally published in The Tan Sheet
Executive Summary
The necessity of 180-day generic exclusivity should be reviewed, FDA Associate Counsel for Drugs Elizabeth Dickinson said at the Food & Drug Law Institute's Hatch/Waxman conference in Washington, D.C. Dec. 11.